Phase III Trial Data Show Lenacapavir Demonstrated 100% Efficacy Preventing HIV in Cisgender Women

Results of the PURPOSE 1 trial indicated that a twice-yearly injection of lenacapavir outperformed the once-daily…

Novel Therapy Shows Significant Promise Slowing Parkinson Disease Progression

Data from an early phase trial published in Nature found that Parkinson disease patients treated with…

Beyond the Numbers: Extrapolating Today’s Trends Forward

Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future…

Utilizing Biomarkers to Develop First-in-Class Antibody Drug Conjugates to Treat Advanced Solid Tumors

In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline…

FDA Approves AbbVie’s Skyrizi for the Treatment of Adults with Moderate to Severely Active Ulcerative Colitis

Approval of Skyrizi marks the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn…

FDA Approves Merck’s Keytruda in Combination with Carboplatin and Paclitaxel to Treat Advanced or Recurrent Endometrial Carcinoma

Approval of Keytruda combination for patients with primary advanced or recurrent endometrial carcinoma is based on…

FDA Approves Merck’s Keytruda in Combination with Carboplatin and Paclitaxel to Treat Advanced or Recurrent Endometrial Carcinoma

Approval of Keytruda combination for patients with primary advanced or recurrent endometrial carcinoma is based on…

FDA Approves Amgen’s Blincyto to Treat CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia

The approval of Blincyto was based on results from the Phase III E1910 clinical trial, which…

CalPERS Names Blue Shield of California as Sole Health Plan Provider

This is the first time in 20 years that CalPERS has changed its sole health plan…

Pharmaceutical Executive: June 2024 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in…